枫蓼肠胃康胶囊联合常规三联治疗慢性萎缩性胃炎伴肠上皮化生的效果  

Effect of Fengliao Changweikang Capsule Combined with Routine Triple Therapy on Chronic Atrophic Gastritis with Intestinal Metaplasia

作　　者：李燕君[1] LI Yanjun(Shenzhen Hospital of Traditional Chinese Medicine,Shenzhen 518114,China)

机构地区：[1]广东省深圳市中医院,广东深圳518114

出　　处：《中国医学创新》2020年第19期149-153,共5页Medical Innovation of China

摘　　要：目的:研究枫蓼肠胃康胶囊联合常规三联治疗慢性萎缩性胃炎伴肠上皮化生的效果.方法:选取2017年10月-2018年10月本院收治的100例慢性萎缩性胃炎伴肠上皮化生患者为研究对象.采用随机数字表法将其分为试验组和对照组,每组50例.对照组予以常规三联治疗,试验组在对照组的基础上加用枫蓼肠胃康胶囊治疗.比较两组临床疗效、中医症状积分、肿瘤坏死因子(TNF-α)、白介素-12(IL-12)、白介素-6(IL-6)、C反应蛋白(hs-CRP)水平,并比较两组治疗后不良反应发生情况和幽门螺杆菌(Hp)的根除率.结果:试验组治疗总有效率为92.00%,显著高于对照组的58.00%,差异有统计学意义(P<0.05).治疗后,两组胃脘胀满、胃脘疼痛、嗳气泛酸、食后脘闷、胃中嘈杂、饮食减少症状积分均降低,且试验组均显著低于对照组,差异均有统计学意义(P<0.05).治疗后,两组TNF-α、IL-12、IL-6、hs-CRP水平均降低,且试验组上述指标均低于对照组,差异均有统计学意义(P<0.05).试验组Hp根除率为82.00%,高于对照组的60.00%,差异有统计学意义(P<0.05).试验组不良反应发生率为6.00%,低于对照组的20.00%,差异有统计学意义(P<0.05).结论:枫蓼肠胃康胶囊辅助治疗慢性萎缩性肠胃炎伴肠上皮化生临床疗效理想,能有效改善临床症状及降低炎症因子水平,且不良反应发生率低.Objective:To study the effect of Fengliao Changweikang Capsule combined with routine triple therapy on chronic atrophic gastritis with intestinal metaplasia.Method:A total of 100 patients with chronic atrophic gastritis accompanied by intestinal metaplasia admitted to our hospital from October 2017 to October 2018 were selected as the research objects.They were divided into experimental group and control group with 50 cases in each group by random number table method.The control group received routine triple therapy,the experimental group was treated with Fengliao Changweikang Capsule on the basis of the control group.The clinical efficacy,TCM symptom scores,tumor necrosis factor-α(TNF-α),interleukin-12(IL-12),interleukin-6(IL-6),and C-reactive protein(hs-CRP)levels were compared between the two groups,the incidence of adverse reactions after treatment and the eradication rate of Helicobacter pylori(Hp)were compared between the two groups.Result:The total effective rate of the experimental group was 92.00%,significantly higher than 58.00%of the control group,the difference was statistically significant(P<0.05).After treatment,the scores of symptoms of epigastric fullness,epigastric pain,belching acid,epigastric flatulence,gastric noise,and reduced diet in both groups were all reduced,and the scores of symptoms in the test group were significantly lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the levels of TNF-α,IL-12,IL-6 and hs-CRP in both groups were decreased,the above indicators in the test group were lower than those in the control group,with statistically significant differences(P<0.05).The Hp eradication rate in the experimental group was 82.00%,higher than 60.00%in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the experimental group was 6.00%,lower than 20.00%in the control group,with a statistically significant difference(P<0.05).Conclusion:Fengliao Changweikang Capsule has an idea

关 键 词：枫蓼肠胃康胶囊 慢性萎缩性胃炎伴肠上皮化生 三联治疗 炎症因子水平 

分 类 号：R573.32[医药卫生—消化系统]